SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 33 of 83
Word Count: 1473
Character Count: 9557

Document Content:

(or approximately $ million if the underwriters exercise their over-allotment option in full), after deducting estimated offering expenses payable by us, and based upon an assumed initial public offering price of $ per share, the midpoint of the estimated price range set forth on the cover page of this prospectus. intend to use the net proceeds from this offering as follows: ● approximately $ (or approximately $ million if the underwriters exercise their over-allotment option in full), or approximately 60% of the net proceeds from this offering, to fund the RELIVE Trial and the associated manufacturing activities required to support such trial; and ● approximately $ (or approximately $ million if the underwriters exercise their over-allotment option in full), or approximately 40% of the net proceeds from this offering, for working capital and other general corporate purposes, including regulatory compliance, intellectual property protection, additional employee hires and additional contractor retainment.

$1.00 increase (decrease) in the assumed initial public offering price would increase (decrease) the net proceeds to us from this offering
by approximately $           million, after deducting the estimated underwriting discounts,
non-accountable expense allowance and estimated aggregate offering expenses payable by us and assuming no change to the number of shares
of common stock offered by us as set forth on the cover page of this prospectus.

We may change the amount of net proceeds to be used
specifically for any of the foregoing purposes. The amounts and timing of our actual expenditures will depend upon numerous factors,
including factors within our discretion and factors outside of our control. We may also use a portion of the net proceeds to acquire,
license and invest in complementary product candidates, technologies, or additional businesses; however, we currently have no agreements
or commitments with respect to any such transaction.

Moreover,
the foregoing represents only our current
intentions based upon our present plans and business conditions to allocate and use the net proceeds from this offering. You are cautioned
that the nature, amounts and timing of our actual expenditures may vary significantly from what is described above or elsewhere
in this prospectus depending on numerous factors. As a result, our management has and will retain broad discretion over the allocation
of the net proceeds from this offering. We may find it necessary or advisable to in our business judgement to use the net proceeds
from this offering for other purposes. Also, if an unforeseen event occurs or business conditions change, we may use the proceeds
of this offering differently than as described above or elsewhere in this prospectus.

Pending our use of the net proceeds from
this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade,
interest-bearing instruments, and U.S. government securities.

addition, as a general matter, given our limited
operating history, early stage of business and a new and unproven technology model, it is difficult to evaluate our business prospects
and actual expenditures in the future. Further, our business plan will be very costly, far more costly than the net proceeds we will
receive from this offering. To develop and implement our business as currently planned, we will need to raise substantial amounts of
additional capital and we intend to raise such additional capital through public or private offerings of equity or equity-linked securities,
traditional loans, commercial collaborations such as licenses or joint ventures and, if available or desirable, government funding, including
grants. No assurances can be given that we will be able to raise additional capital when needed, and our inability to raise additional
capital could lead to the failure of our company.

DIVIDEND
POLICY

have never declared or paid any cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable
future. The payment of dividends, if any, in the future is within the discretion of our board of directors and will depend on our earnings,
capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to
finance the development and growth of our business.

CAPITALIZATION

The
following table sets forth our cash and equivalents and capitalization as of December 31, 2025:

an actual basis;

a pro forma basis to give effect to: the issuance of 7,277,645 shares of common stock upon the closing of this offering in connection with the conversion of: (i) 1,565,000 shares of
our existing Series A Preferred Stock into 1,565,000 shares of common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00) and (ii) $11,333,146 of our existing convertible notes into 6,099,988
shares of our common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00); and

a pro forma as adjusted basis to give effect to: (i) our issuance and sale of              shares of our common stock in this offering at the
assumed initial public offering price of $              per share (the midpoint of the estimated price range set forth on the cover page of this
prospectus) and (ii) the deduction of $              of underwriting discounts and $              of estimated offering expenses payable by us, assuming the
underwriters do not exercise any portion of their over-allotment option.

The
information set forth in the table below is illustrative only and will be adjusted based on the actual initial public offering price
and other terms of this offering as determined at pricing. You should read this table together with “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” and our audited financial statements and related notes and unaudited
interim condensed financial statements and related notes thereto included elsewhere in this prospectus.

As of December 31, 2025

Actual Pro Forma Pro
Forma As
Adjusted

Cash and cash equivalents $	1,838,121 $

Total liabilities 15,134,042

Stockholders’ Equity:

Preferred Stock: Par value of $0.0001 per share, 1,565,000 shares issued and outstanding, actual; par value of $0.0001 per
share, no shares issued and outstanding, pro forma and pro forma as adjusted. 157

Common Stock: Par value of $0.0001 per share, 5,712,645 shares issued and outstanding, actual; par value of $0.0001 per share,
shares issued and outstanding, pro forma; par value of $0.0001 per share           shares
issued and outstanding, pro forma as adjusted. 571

Additional paid-in capital 218,675,435

Accumulated deficit (231,241,344	)

Total stockholders’ equity (11,965,181	)

Total capitalization $	2,568,861 $

The
number of shares of our common stock to be outstanding upon completion of this offering will be
shares assuming no exercise of the over-allotment by
the underwriters, which is based on 5,712,645 shares of our common stock outstanding as of December 31, 2025, and
includes 7,664,988 shares of common stock being issued upon the closing of this offering in connection with the conversion
of: (i) 1,565,000 shares of our existing Series A Preferred Stock into 1,565,000 shares of common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00) and (ii) $11,333,146 of our existing
convertible notes into 6,099,988 shares of our common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00), and excludes, as of the date of this prospectus:

●	shares of common stock issuable upon the exercise of the Representative’s Warrant;

shares of our common stock reserved for issuance under stock option agreements issued pursuant to the 2024 Plan; and

shares of our common stock (which is equal to         % of our issued and outstanding common
stock immediately after the consummation this offering) reserved for future issuance under the 2026 Plan, which will
become effective as of the closing of this offering.

Each
$1.00 increase (decrease) in the assumed initial public offering price of $        per share (the midpoint of the estimated price range set
forth on the cover page of this prospectus) would increase (decrease) the amount of cash, additional paid-in capital, total stockholders’
equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately $          , assuming the number of shares, as set
forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and estimated offering expenses
payable by us. Similarly, each increase (decrease) of           shares offered by us would increase (decrease) cash, total stockholders’
equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately $         , assuming the assumed initial public offering
price of $          per share (the midpoint of the estimated price range set forth on the cover page of this prospectus) remains the same, and
after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information
discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering
determined at pricing.

DILUTION